Sign up
Pharma Capital

Clinigen set to snap up Quantum Pharma in £150mln cash-and-shares deal

Clinigen said Quantum is a “sound cultural fit” and the acquisition should provide “immediate financial benefits”
scientist looking through a microscope
The acquisition makes sense given both firms' focus on developing niche medicines

Clinigen Group PLC (LON:CLIN) is closing in on the acquisition of fellow AIM-listed specialty pharma Quantum Pharma PLC (LON:QP.) after the two agreed a £150mln cash-plus-shares deal.

The offer, which has been recommended by Quantum to its shareholders, will see Clinigen pay 37p in cash and 0.0405 new Clinigen shares for each Quantum share.

WATCH: Andrew Hoare on Clinigen's well-timed swoop on Quantum Pharma

Based on Clinigen’s closing price of £11.11 yesterday, that values each Quantum share at 82p and the total offer at £150.3mln.

‘Sound cultural fit’

Clinigen, which began discussions over a possible takeover last month, said Quantum was a “sound cultural fit” and that the acquisition would add “immediate financial benefits”.

The company – which is worth more than £1bn – added that Quantum provides it with a European presence while its international footprint can give Quantum a global reach for its generic licensed products.

WATCH: Quantum Pharma acquisition 'the logical next step' in growth story for Clinigen

The acquisition is also expected to “enhance Clinigen’s position as the global leader in ethical access to unlicensed medicines”.

Merger set to benefit both firms

"The earnings enhancing acquisition of Quantum is an excellent operational and geographical, as well as cultural, fit with Clinigen,” said Clinigen chief executive Shaun Chilton.

“Quantum's UL2L (unlicensed to licensed) capabilities will provide a bridge between our unlicensed and commercial businesses, mirroring our business in the AAA region. Quantum's expertise in this area will enable us to boost our global UL2L ambitions.

READ: Clinigen confirms it is in talks to take over Quantum Pharma

"With the addition of Quantum, we will be in a stronger position to drive our global expansion in the unlicensed and commercial medicine markets."

Quantum boss Chris Rigg added: "The Quantum board is excited by the prospects of the enlarged group and Quantum's role in it."

WATCH: Clinigen achieves a pharma first with EC Cardioxane approval

The acquisition is being funded from existing banking facilities.

Clinigen said it has received irrevocable undertakings – investors who have agreed to sell their shares – from Quantum shareholders representing 19% of the share capital.

View full CLIN profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.